Table 2 Clinical trials of tocilizumab for cytokine release syndrome
From: Cytokine release syndrome: grading, modeling, and new therapy
NCT no. | Trials | Conditions | Interventions | Locations |
|---|---|---|---|---|
03533101 | Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation | •Cytokine release syndrome •Stem cell transplant complications | •Drug: tocilizumab | •Hospital Universitario Dr. Jose E Gonzalez UANL, Monterrey, Nuevo Leon, Mexico |
03275493 | Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia | •Acute lymphoblastic leukemia •CD19 positive •Relapse •Refractory | •Biological: humanized CD19 CAR-T cells •Biological: humanized CD19 CAR-T cells with CRS suppression technology | •The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China |
02906371 | Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome | •Lymphoblastic leukemia, acute, childhood | •Drug: tocilizumab •Biological: CART 19 | •Children’s Hospital of Philadelphia, Philadelphia, PA, USA |